AMARIN®

Vascepa®
(icosapent ethyl)



Leading a New Paradigm in Preventative Cardiovascular Care

Investor Presentation

November 2021

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA®(VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and milestones. These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

This presentation is intended for communication with investors and not for drug promotion.

Cardiovascular Disease (CVD) Is an Enormous and Worsening Public Health Burden

US CVD BURDEN

1 stroke, heart attack or death from CVD
every 13 seconds in the US[1]

$555bn
annual treatment cost expected to double in 20 years[2]

38.9M
patients on statins[3]

EUROPE CVD BURDEN

~50M with CVD
in Europe[4]

€210bn
annual spending on CV disease management[5]

3.9M
People die each year from a heart attack or a stroke[4]

INTERNATIONAL CVD BURDEN

523M
living with CVD globally[6]

>$1.0tn
estimated economic burden by 2030[7]

China alone
291M with CVD & the leading cause of death[8]

Leading cause of death globally | Increasing prevalence | High and increasing economic burden

1 Heart Disease in the United States: 2020; 2 Cardiovascular Disease: A Costly Burden for America Projections Through 2035; 3 IMS Data: 2020; 4 European Heart Network Report, 2017; 5 ESC Cardiovascular Realities 2020 report; 6 IMS Data 7 Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 – 2020 8 WEF-Harvard Global Economic Burden 9 China Cardiovascular Diseases Report 2018: an updated summary – Jan 2020

Lowering LDL-C Helps But is Not Enough for Many Patients

Controlled LDL-C doesn't eliminate CV risk; P-CVR often remains 25%-35% lowering major adverse CV events (MACE) shown in CV outcome studies of statin therapies

P-CVR – Persistent Cardiovascular Risk



Placebo groups from multiple recent trials show high P-CVR despite statin-based standard-of-care
14.6% to 34.7% of patients treated for LDL-C but not for P-CVR experienced a major adverse cardiovascular event (MACE) in 3-7 Years



Cross-trial comparisons are subject to differences in populations, primary outcomes, and other trial design aspects

AMARIN

Note: FOURIER, REDUCE-IT® and IMPROVE-IT trials evaluated evolocumab, icosapent ethyl and ezetimibe / simvastatin, respectively
* 67 mg/dL is equivalent to 0.8 mmol/L and 92 mg/dL is equivalent to 1.0 mmol/L

1. Sabatine MS, et al. *N Engl J Med*. 2017;376(18):1713-1722; 2. Bhatt DL, et al; for REDUCE-IT® Investigators. *N Engl J Med*. 2019;380(1):11-22; 3. Cannon CP, et al. *N Engl J Med*. 2015;372(25):2387-2397

CV Drug Development:
A Challenging Endeavor

- Many biopharma abandoned drug development in CV
- Requirements for long-term outcomes studies evaluating thousands of patients take years to fulfill
- Significant costs to fund the commercial infrastructure needed for broad primary care reach

Amarin:
Succeeding in a Challenging Environment

- With REDUCE-IT®, developed the first and only approved medication for reducing cardiovascular risk beyond LDL lowering therapies in certain high-risk, statin-treated, patients
- Received US FDA approval with unanimous Advisory committee positive vote of 16:0
- Received European Medicines Agency (EMA) approval for a broad label in-line with the REDUCE-IT evidence

VASCEPA/VAZKEPA has Demonstrated CV Risk Reduction Beyond Standard-of-Care (including Statins) in Landmark CVOT



- ✓ Significant reductions across the prespecified testing hierarchy [1]
- ✓ Generally consistent reductions across subgroups
- ✓ Analyses suggest lipid, lipoprotein, and inflammatory markers (including TG) likely have limited contribution to the overall CV benefit demonstrated with icosapent ethyl (IPE)
- ✓ Analysis suggests CV benefit derived from multifactorial effects of icosapent ethyl administered at high levels
- ✓ Well-tolerated safety profile with overall adverse event rates similar for both VASCEPA and placebo patients as per US FDA, Health Canada, and European Commission approved labels for VASCEPA/VAZKEPA and peer-reviewed publication

HR = hazard ratio; NNT = number needed to treat

1. Bhatt DL et al; for REDUCE-IT® Investigators. *N Engl J Med. 2019;380(1):11-22*

AMARIN

VASCEPA/VAZKEPA Has the Lowest NNT Among New Therapies Proven to Reduce MACE When Added to Current Standard-of-Care

Statin monotherapy | **On top of statin therapy**



Results on left are based on first occurrence of MACE;*

VASCEPA/VAZKEPA in total events analysis (first and recurring MACE) resulted on average in 1 fewer MACE per 6 patients treated

NNT: Number of patients who need to be treated to prevent one additional bad outcome

***Based on primary composite endpoints of each trial**

Note: Cross-trial comparisons are subject to differences in populations, primary outcomes, study duration and other trial design aspects. Information provided for context only; none of the products have same indication as Vascepa®

1. LaRosa JC, et. al., N Engl J Med 2005;352:1425-35; 2. Cannon CP, et al. *N Engl J Med.* 2015;372(25):2387-2397; 3. Sabatine MS, et al. *N Engl J Med.* 2017;376(18):1713-1722; 4. Bhatt DL et al; for REDUCE-IT® Investigators. *N Engl J Med.* 2019;380(1):11-22

AMARIN

Vascepa® (icosapent ethyl)

VASCEPA/VAZKEPA is a Preventative Cardiovascular (CV) Care Treatment Option Beyond LDL-C Lowering

VASCEPA/VAZKEPA is the only drug proven to reduce persistent CV risk in the population studied (P-CVR)



AMARIN

Broad Third-Party Support for Icosapent Ethyl

COST EFFECTIVE BY ICER

20+ leading medical societies recognizing importance of Icosapent Ethyl:

- American Association of Clinical Endocrinologists
- American College of Cardiology
- American Diabetes Association
- American College of Endocrinology
- American Heart Association
- American Stroke Association
- Brazilian Society of Cardiology
- Canadian Cardiovascular Society
- Canadian Stroke Best Practice Recommendations Advisory Committee, in collaboration with the Canadian Stroke Consortium
- Chinese Society of Cardiology
- Chinese Journal of Internal Medicine (a journal of the Chinese Medical Association)
- Colombian Society of Cardiology & Colombian Association of Endocrinology, Diabetes and Metabolism
- Egyptian Heart Journal
- Endocrine Society
- European Society of Cardiology
- European Association of Preventive Cardiology
- European Atherosclerosis Society
- Japanese Circulation Society
- National Lipid Association
- Thrombosis Canada

ENDOCRINE SOCIETY

American College of Endocrinology 1993 ACE

American Association of Clinical Endocrinologists AACE

nla NATIONAL LIPID ASSOCIATION

American Diabetes Association

European Atherosclerosis Society

Thrombosis Canada / Thrombose Canada

ESC European Society of Cardiology

Sociedade Brasileira de Cardiologia SBC 1943

American Heart Association

Asociación Sociedad Colombiana de Cardiología & Cirugía Cardiovascular

Japanese Circulation Society

AMARIN

The Institute for Clinical and Economic Review (ICER) confirms the cost effectiveness of Vascepa across all of the non-profit organization's analyses, based on its Quality-adjusted life year (QALY) metrics of <$50,000. October 2017

Amarin Future Growth Strategy



Significant Growth Opportunity for VASCEPA/VAZKEPA

US → Before 2021: Mostly R&D and US Commercial Focus → **Europe** → 2021 and Beyond: Expanding to Europe and Int'l → **International**

Approved for lowering cardiovascular risk (2019) and treating severe hypertriglyceridemia (original niche indication – 2012)

YTD21 net revenue of **~$439 million**

Limited **generic** competition

Approved for lowering cardiovascular risk (2021)

10y regulatory data protection period – no direct competitor

- **Launched in Germany** - Sept 2021
- Market access dossiers filed in 10 countries;

Gain access to ~20 additional countries to reach the top 50 cardiometabolic markets in the world.

- **Canada**: **Launched** via partner in 2020
- **China**: **submission accepted** - anticipated decision near YE21
- **Middle East**: **Launched** via distributor in select countries for TG lowering; now pursuing P-CVR indications
- Initiating regulatory filing processes for **Australia, New Zealand,** and **Israel** plus up to 3 others in 2022

Amarin US Revenue by quarter



AMARIN

Source: IQVIA SMART, Jan 1992 - Dec 2011; Symphony PHAST, Jan 2010 - Sept, 2021
Statin Brands included are Pravachol, Zocor, Lipitor, Crestor

Third Quarter Financial Highlights

- Total year-to-date US product revenue, net of $435.1 million, compared with $432.2 million in 2020
- Total Q3'21 US product revenue, net of $140.8 million, compared with $154.7 million in Q3'20
- U.S. VASCEPA franchise is profitable
- Based on Symphony Health data, Amarin retained approximately 83% and 87% of the IPE market in the three and nine months ended September 30, 2021, respectively, compared with generics
- $517.9 million in cash and investments and no debt
- Strong balance sheet to support growth and expansion plans

Amarin Go-To-Market Strategy to Drive Growth in the US



Expanding Healthcare Provider Engagement:

3-4X amplification of physicians reach through digital channels
Sales force optimization to focus on the most productive and accessible territories

Managed Care Access Enhancement:

Drive incremental volume growth through further removing barriers to VASCEPA Rx to ensure that patients in need of CV risk reduction receive proper therapy

Optimizing VASCEPA Prescriptions for CV Risk Reduction:

Address gaps in Prescribing Ecosystem to Reduce Inappropriate Generic Substitution
Evaluating various innovative solutions designed to better manage IPE Rx for CVRR

ZS AccessMonitor™ reveals that 29% of physicians were accessible in the second half of 2020, a significant recovery from a mere 7% accessible physicians in first half of 2020

Accessible Physicians Trend*



AMARIN

*HCPs with AM No-See Rating of 8 to 10 are considered to be accessible
*Based on 240k to 350k Physicians who have been evaluated in different semesters

Reproduced with permission from ZS AccessMonitor™

Amarin Future Customer Engagement Ecosystem

- 360º view of the customer and interactions by Amarin Team
- Amplify and expand sales force reach via orchestrated omnichannel engagement to achieve customer reach, coverage, share of voice & prescriptions
- Utilize data & insights to provide meaningful & relevant customer engagement
- Building an Amarin owned ecosystem
  - Digital reach & presence supported by 3rd party vendors in the short term
  - Mid- to long-term building the Amarin owned digital reach
- Leveraging strategic partners to setup & operate customer engagement ecosystem



Prescribing/Dispensing Ecosystem is Designed to Maximize Generic Prescribing/Dispensing





US E-Pharmacy Partnership

- Amarin has partnered with BlinkRx, a unique patient access solution, for its flagship product, VASCEPA.
- BlinkRx provides an enhanced, digital-first prescription fulfillment channel, that eliminates the barriers to starting and remaining on Vascepa.
- Patients benefit from transparent low prices, free home delivery, and world-class support.

Launched VAZKEPA in Germany

Relentless focus on education, awareness & access

- Successful launch event-Sep
- Electronic prescribing system -Oct
- 60 events hosted to date
- 50+ approved and/or in planning

AMARIN

3.9M deaths per year in Europe due to CVD[1]

~€210B annual CVD costs to European Union[1]

10+ years of market exclusivity in Europe

VAZKEPA in Europe:
A *Significant Market Opportunity*

- ✓ Filed market access dossiers in ten key EU countries ahead of YE schedule
- Multiple EU country launches expected in 2022
- Plans to file next wave of five market access dossiers in 2022
- Dynamic Go-to-Market strategy includes significant digital initiatives to efficiently enhance and expand customer engagement
- Customized, bespoke model easily adapted to the specificities of individual markets

1) European Heart Network. European Cardiovascular Disease Statistics 2017. https://ehnheart.org/cvd-statistics/cvd-statistics-2017.html. Accessed August 2021

Amarin to Unlock Revenue Potential in 20 Additional Markets Internationally



[1] For cardiovascular risk reduction indication; [2] For severe hypertriglyceridemia indication; original U.S. NDA approval in July 2012;

International Growth Represents Potential $1B Opportunity

Plans to Bring Unique Cardioprotective Benefits of VASCEPA/VAZKEPA to 20 Additional Markets

1st Wave 2022

6 Countries

2nd Wave 2023

9 Countries

3rd Wave 2024

5 Countries

Supported by REDUCE-IT Study and U.S. FDA and EMA Filings

AMARIN

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary between market to market.

Amarin: An Exciting Opportunity to Create Value

U.S.

- Grow and defend VASCEPA despite generics' presence on the market for the VHTG indication
- Advance the Go-to-Market digital omnichannel model to drive greater awareness and demand

EU

- Build awareness of VAZKEPA across EU as we prepare for strong sequenced launches in key markets throughout 2022
- Value based proposed list price of ~€200 or $240 monthly

Intl

- Bring CV benefits of VASCEPA to ~20 additional markets internationally
- Initiate the regulatory processes and obtain additional approvals in First Wave in 2022

Future

- Seek partnerships and opportunities to leverage growing global commercial infrastructure and competent R&D team

Thank you

AMARIN